2.7.4. Assay of human coagulation factor VIII

Human coagulation factor VIII is assayed by its biological activity as a cofactor in the activation of factor X by activated factor IX (factor IXa) in the presence of calcium ions and phospholipid. Factor VIII activity may be measured in plasma preparations and therapeutic concentrates (plasma-derived and recombinant). The potency of a factor VIII preparation is estimated by comparing the quantity necessary to achieve a certain rate of factor Xa formation in a test mixture containing the substances that take part in the activation of factor X, and the quantity of the International Standard, or of a reference preparation calibrated in International Units, required to produce the same rate of factor Xa formation.

Quantification of factor VIII activity in plasma preparations is expressed in International Units defined by the International Standard for blood coagulation factor VIII in plasma, and coagulation factors V, VIII, XI and XIII plasma BRP is suitable for use as a reference preparation. Quantification of factor VIII activity in therapeutic concentrates is expressed in International Units defined by the International Standard for blood coagulation factor VIII concentrate, and human coagulation factor VIII concentrate BRP is suitable for use as a reference preparation.

The chromogenic assay method consists of 2 consecutive steps: the factor VIII-dependent activation of factor X in a coagulation-factor reagent composed of purified components, and the enzymatic cleavage of a chromogenic factor Xa substrate to yield a chromophore that can be quantified spectrophotometrically. Under appropriate assay conditions, there is a linear relation between the rate of factor Xa formation and the factor VIII concentration. The assay is summarised by the following scheme.

\[
\text{factor X} \xrightarrow{\text{activated factor VIII}} \text{factor Xa, phospholipid, Ca}^{2+} \xrightarrow{\text{factor Xa}} \text{peptide + chromophore}
\]

**Step 1**

Prepare all dilutions in plastic tubes and use immediately.

Prepare dilutions of the pre-diluted reference and test preparations and of the preparation to be examined with an appropriate buffer solution, for example, tris(hydroxymethyl)aminomethane or imidazole, containing 1 per cent of human or bovine albumin. Prepare at least 2 dilution series of at least 3 further dilutions each lacking the ability to generate factor Xa on its own. One of the reagents contains calcium ions. After reconstitution, the reagents may be combined provided that no substantial amounts of factor Xa are generated in the absence of factor VIII. In the final incubation mixture, factor VIII must be the only rate-limiting component.

**Step 2**

Both steps employ reagents that may be obtained commercially from a variety of sources. Although the composition of individual reagents may be subject to some variation, their essential features are described in the following specification. Deviations from this description may be permissible provided that it has been shown, using the appropriate International Standard for blood coagulation factor VIII as the standard, that the results obtained do not differ significantly.

It is important to demonstrate by validation the suitability of the kit used, notably by checking the time course of factor Xa generation in order to determine the time taken to reach 50 per cent of the maximal factor Xa generation.

**REAGENTS**

The coagulation factor reagent comprises purified proteins derived from human or bovine sources. These include factor X, factor IXa, and a factor VIII activator, usually thrombin. These proteins are partly purified, preferably to at least 50 per cent, and do not contain impurities that interfere with the activation of factor VIII or factor X. Thrombin may be present in its precursor form prothrombin, provided that its activation in the reagent is sufficiently rapid to give almost instantaneous activation of factor VIII in the assay. Phospholipid may be obtained from natural sources or be synthetically prepared, and must, to a substantial extent, consist of the species phosphatidylserine. The components of the complete reagent are usually divided into at least 2 separate reagents, each lacking the ability to generate factor Xa on its own. One of the reagents contains calcium ions. After reconstitution, the reagents may be combined provided that no substantial amounts of factor Xa are generated in the absence of factor VIII. In the final incubation mixture, factor VIII must be the only rate-limiting component.

The 2nd step comprises the quantification of the formed factor Xa, employing a chromogenic substrate that is specific for factor Xa. Generally this consists of a derivatised short peptide of between 3 and 5 amino acids, joined to a chromophore group. On cleavage of this group from the peptide substrate, its chromophoric properties shift to a wavelength allowing its spectrophotometric quantification. The substrate must also contain appropriate inhibitors to stop further factor Xa generation, e.g. chelating agents, and to suppress thrombin activity.

**ASSAY PROCEDURE**

For the assay of therapeutic concentrates, add sufficient pre-diluent to the reference and test preparations to produce solutions containing 0.5-2.0 IU/mL. The pre-diluent consists of haemophilia A plasma, or of an artificially prepared reagent that contains sufficient von Willebrand factor and that gives results that do not differ significantly from those obtained employing haemophilia plasma. The pre-diluted materials must be stable beyond the time required for the assay. Pre-dilution in haemophilia A plasma is not required for the assay of factor VIII in plasma preparations.

Prepare dilutions of the pre-diluted reference and test concentrate preparations (or the reference and test plasma preparations) using a non-chelating, appropriately buffered solution, for example, tris(hydroxymethyl)aminomethane or imidazole, containing 1 per cent of human or bovine albumin. Prepare at least 2 dilution series of at least 3 further dilutions for each material. Prepare the dilutions such that the final factor VIII concentration in the reaction mixture is preferably below 0.01 IU/mL, during the step of factor Xa generation.

Prepare a control solution that includes all components except factor VIII.

Prepare all dilutions in plastic tubes and use immediately.

**Step 1**

Mix prewarmed dilutions of the factor VIII reference preparation and of the preparation to be examined with an appropriate volume of the prewarmed coagulation factor reagent or a combination of its separate constituents, and incubate the mixture in plastic tubes or microplate wells at 37 °C. Allow the activation of factor X to proceed for a suitable time, terminating the reaction (step 2) when the factor Xa concentration has reached approximately 50 per cent of the maximal (plateau) level. Appropriate activation times are usually between 2 min and 5 min.

**Step 2**

Terminate the activation by addition of a prewarmed reagent containing a chromogenic substrate. Quantify the rate of substrate cleavage, which must be linear with the concentration of factor Xa formed, by measuring the absorbance change at an appropriate wavelength using a spectrophotometer, either monitoring the absorbance continuously, thus allowing the initial rate of substrate cleavage to be calculated, or terminating the hydrolysis reaction after a suitable interval by lowering the pH by addition of a suitable reagent, such as a 50 per cent V/V solution of acetic acid, or a 1 M pH 3 citrate buffer solution. Adjust the hydrolysis time to achieve a linear development of chromophore over time. Appropriate hydrolysis times are usually between 3 min and 15 min, but deviations are permissible if better linearity of the dose-response relationship is thus obtained.

Calculate the potency of the test preparation by the usual statistical methods (for example, 5.3).